Catalog No.
Product Name
Application
Product Information
Citations
-
CCK-A receptor antagonist
Loxiglumide (CR1505) is a cholecystokinin antagonist -
CCK-2 receptor antagonist
Z-360 is a selective, orally available, 1,5-benzodiazepine-derivative gastrin/cholecystokinin 2 (CCK-2) receptor antagonist with potential antineoplastic activity. -
CCK antagonist
Proglumide sodium salt is a non-selective cholecystokinin (CCK) antagonist. It inhibits CCK-stimulated amylase secretion and prevents CCK-induced 2-deoxyglucose uptake in mouse pancreatic acini. -
CCK-2 receptor antagonist
Nastorazepide is a selective, orally available, 1,5-benzodiazepine-derivative gastrin/cholecystokinin 2 (CCK-2) receptor antagonist with potential antineoplastic activity. -
CCK antagonist
Proglumide is a drug that exerts an inhibitory effect on gastric secretion and reduces gastrointestinal motility. IProglumide is a known cholecystokinin (CCK) antagonist. -
ligand-linker conjugate
CCK2R Ligand-Linker Conjugates 1 is a ligand-linker conjugate, which conjugates to the cytotoxic antimicrotubule agents Desacetyl Vinblastine Hydrazide (DAVBH) and Tubulysin B Hydrazide (TubBH) via a hydrophilic peptide linker. -
CCKA receptor antagonist
Dexloxiglumide is a selective cholecystokinin type A (CCKA) receptor antagonist. Dexloxiglumide, the active enantiomer of Loxiglumide, inhibits smooth muscle cell contractions induced by cholecystokinin-octapeptide (CCK-8). -
Gastrin/CCK-B antagonist
Sograzepide (Netazepide; YF 476; YM-220) is an extremely potent , highly selective and orally active Gastrin/CCK-B antagonist with an IC50 value of 0.1 nM, has inhibitory effect on Gastrin/CCK-A activity with an IC50 of 502 nM. - Ceruletide is a decapeptide and a potent cholecystokinin receptor agonist. Ceruletide is a safe and effective cholecystokinetic agent with a direct spasmogenic effect on the gallbladder muscle and bile ducts.
- Gastrin I, human is the endogenous peptide produced in the stomach, and increases gastric acid secretion via cholecystokinin 2 (CCK2) receptor.
- [Leu15]-Gastrin I (human) is a peptide. Gastrin exerts its function through G-protein-coupled receptor called the cholecystokinin (CCK) or CCK-B receptor (CCK-BR).
- Cholecystokinin Octapeptide, desulfated is a synthetic desulfated octapeptides of cholecystokinin (CCK).
- Tetragastrin (Cholecystokinin tetrapeptide; CCK-4) is the C-terminal tetrapeptide of gastrin. Tetragastrin can stimulate gastric secretion. Tetragastrin is a Cholecystokinin (CCK-4) receptor agonist. Gastric mucosal protection.
- N-acetyl CCK-(26-30) amide (CCK-(26-30) (sulfated)) is a cholecystokinin (CCK) receptor antagonist.
- CCK (26-31) (non-sulfated) is the N-terminal fragment of CCK, a peptide hormone found in the gut and brain that stimulates digestion, regulates satiety, and is associated with anxiety. CCK (26-31) is also less active in non-sulfated than in sulfated form.
-
Amino Acid Polypeptide Hormone Analogue
Sincalide ammonium is an amino acid polypeptide hormone analogue of cholecystokinin (CCK) that primarily targets gallbladder function. It is utilized in clinical settings for its ability to promote gallbladder contraction, thus facilitating the diagnosis of gallbladder and pancreatic disorders. By increasing bile secretion and causing the contraction of the gallbladder while relaxing the sphincter of Oddi, Sincalide ammonium aids in the efficient drainage of bile into the duodenum, making it a valuable tool in postevacuation cholecystography. -
HK Inhibitor
Antibacterial agent 241 is a histidine kinase (HK) inhibitor with IC50 values of 14 μM for CckA and 238 μM for PhoQ. It demonstrates moderate antibacterial activity against various bacterial strains, including E. coli DC2, Bacillus cereus, and Bacillus subtilis, with minimum inhibitory concentration (MIC) values ranging from 12 to 74 μg/mL. This compound is suitable for research applications targeting bacterial signaling pathways and antibiotic resistance mechanisms. -
CCK2R Antagonist
Ceclazepide is a cholecystokinin-2 receptor (CCK2R) antagonist that serves as an orally active inhibitor of Mycobacterium abscessus. This compound effectively reduces acid secretion in rat models and demonstrates significant suppression of both wild-type and multiple subspecies of M. abscessus. Importantly, Ceclazepide inhibits the growth of M. abscessus within macrophages while maintaining cell integrity, making it a valuable tool for research into mycobacterial infections and related therapeutic strategies. -
CCK-BR Antagonist
YM022 is a highly potent and selective antagonist of the gastrin/cholecystokinin (CCK)-B receptor (CCK-BR). With Ki values of 68 pM for CCK-B and 63 nM for CCK-A, YM022 effectively blocks gastrin-induced gastric acid secretion and inhibits histidine decarboxylase activation in vivo. This compound is valuable for research applications related to gastrointestinal disorders and receptor signaling pathways. -
CCKBR Agonist
CCKBR agonist-1 is a potent agonist of the cholecystokinin B receptor (CCKBR), preferentially activating Gq-proteins with an EC50 of 35 pM. This compound enhances neuronal survival, demonstrated by an EC50 of 37 pM, and has shown efficacy in mitigating cognitive decline in murine models. Mechanistically, CCKBR agonist-1 upregulates α-secretase (ADAM10) and the calcium signaling molecule PLCB4, leading to decreased amyloid β (Aβ) plaque formation and enhancement of long-term potentiation (LTP). CCKBR agonist-1 serves as a valuable tool for research into Alzheimer's disease. -
CCKBR Agonist
CCKBR agonist-2 is a selective agonist for the cholecystokinin B receptor (CCKBR), primarily activating the Gi signaling pathway with an EC50 of 0.27 nM. This compound demonstrates minimal interaction with Gq and Gs pathways, making it a valuable tool for studying Gi-mediated cellular responses. Despite its potency in activating CCKBR-Gi signaling, CCKBR agonist-2 does not exhibit significant neuroprotective effects in mouse models of Alzheimer's disease, highlighting the complexity of cognitive function modulation. This reagent is useful in research exploring the roles of CCKBR signaling in various physiological and pathological contexts. -
CCK Receptor Antagonist
Devazepide is a potent, competitive, and selective antagonist of the cholecystokinin (CCK) receptor. It exhibits high affinity with IC50 values of 81 pM, 45 pM, and 245 nM for rat pancreatic, bovine gallbladder, and guinea pig brain CCK receptors, respectively. This nonpeptide agent is primarily utilized in research focused on gastrointestinal disorders, providing insights into gastrointestinal physiology and the therapeutic potential of CCK receptor modulation. -
CCK-B Antagonist
L-365260 is a selective antagonist of the cholecystokinin B receptor (CCK-B), exhibiting high affinity with Ki values of 1.9 nM for non-peptide gastrin and 2.0 nM for brain CCK receptors. It engages competitively and stereoselectively with these receptors, making it valuable in studies of neuropharmacology. Additionally, L-365260 has been shown to enhance morphine analgesia while preventing the development of morphine tolerance, highlighting its potential utility in pain management research. -
Cholecystokinin Receptor Antagonist
Lorglumide sodium is a potent cholecystokinin (CCK) receptor antagonist that inhibits the action of CCK, a peptide hormone involved in digestion and satiety. Its antagonistic properties make it useful in research applications related to gastrointestinal function, appetite regulation, and the modulation of pain pathways. Lorglumide sodium serves as a valuable tool for studying CCK receptor-mediated signaling and related biological processes. -
CCKA Agonist
A71623 is a potent and highly selective full agonist for the CCK-A receptor, demonstrating a strong affinity with an IC50 of 3.7 nM in guinea pig pancreatic tissues and minimal activity at CCK-B receptors with an IC50 of 4500 nM. Its selectivity makes A71623 a valuable tool for studying CCK-A receptor functions and related physiological processes. This compound is applicable in research exploring gastrointestinal physiology, neurobiology, and the modulation of satiety signaling pathways. -
CCK1 Receptor Antagonist
Lintitript is a highly potent and selective non-peptide antagonist of the cholecystokinin (CCK1) receptor, exhibiting an EC50 of 6 nM and a Ki value of 0.2 nM. It demonstrates over 33-fold selectivity for CCK1 compared to CCK2 receptors, which have an EC50 of 200 nM. This compound is significant in research applications focused on appetite regulation, as it increases plasma concentration of leptin and insulin, thereby influencing food intake. -
CCK2 Antagonist
PNB-001 is a selective antagonist of the cholecystokinin receptor type 2 (CCK2), demonstrating significant anti-inflammatory and analgesic properties. This compound is particularly valuable in research focused on pain management and inflammation pathways. Its oral bioactivity makes it a suitable candidate for in vivo studies examining CCK2 modulation in various biological systems. -
Cholecystokinin Receptor Antagonist
T-0632 is a potent cholecystokinin (CCK) A receptor antagonist that effectively inhibits the binding of [125I]CCK-8 to rat pancreatic CCK A receptors, demonstrating a K_i value of 0.24 nM. It shows significant selectivity in blocking CCK-8-induced pancreatic enzyme release, with an IC_50 value of 5.0 nM. T-0632 exhibits reversible antagonistic effects in rabbit gallbladder smooth muscle, distinguishing it from other CCK A antagonists. This compound is valuable for researching the physiological roles of CCK receptors and their impact on gastrointestinal function. -
Cholecystokinin Receptor Antagonist
LY 225910 is a selective antagonist of the cholecystokinin receptor (CCK2 receptor), primarily impacting the excitatory response associated with morphine. By inhibiting this receptor, LY 225910 plays a significant role in morphine sensitization, making it a valuable tool in research focused on pain management and addiction. Its application can aid in understanding the mechanisms underlying opioid response and potential therapeutic strategies. -
Cholecystokinin Receptor Antagonist
Pranazepide is a selective antagonist of the cholecystokinin-A receptor (CCK-A), implicated in regulating gastrointestinal functions and satiety. This compound exhibits significant biological activity by modulating neural signaling pathways associated with appetite control and gastrointestinal motility. Pranazepide is commonly utilized in pharmacological research focused on obesity, anxiolytic effects, and the role of CCK in the central nervous system. -
CCK2 Receptor Antagonist
JNJ-26070109 is a selective antagonist of the cholecystokinin 2 (CCK2) receptor, exhibiting high-affinity and competitive binding. With favorable pharmacokinetic properties, it demonstrates pKis of 8.49, 7.99, and 7.70 for human, rat, and dog CCK2 receptors, respectively. This compound is particularly relevant for research into gastroesophageal reflux disease, as CCK2 receptors play a dual role in regulating gastric acid secretion and the growth of gastrointestinal mucosa. -
CCK Derivative
Cholecystokinin Octapeptide, desulfated TFA is a synthetic derivative of the endogenous hormone cholecystokinin (CCK), which primarily targets CCK receptors. This peptide exhibits key biological activities related to digestion and satiety regulation, making it valuable in studies of gastrointestinal physiology and appetite control. It is frequently utilized in research applications investigating the role of CCK in various biological processes, including pancreatic enzyme secretion and gastric motility. -
Cholecystokinin Receptor Antagonist
A-65186 is a cholecystokinin (CCK) A receptor antagonist that effectively inhibits CCK8-induced amylase secretion. This compound exhibits high binding affinity for pancreatic CCK-A receptors and demonstrates over 500-fold selectivity for CCK-A over CCK-B receptors. It serves as a valuable tool in research focused on gastrointestinal physiology and the role of CCK signaling in pancreatic function. -
Cholecystokinin Receptor Antagonist
(Rac)-Sograzepide functions as an antagonist of the cholecystokinin B (CCK-B) receptor, effectively inhibiting its activity. This compound is primarily utilized in research focused on modulating gastric acid secretion and exploring potential therapeutic strategies for gastrointestinal disorders. Its role in receptor inhibition makes it valuable for studies related to the regulation of digestive processes and related physiological pathways. -
Peptide Hormone
CCK (26-31) sulfated is a peptide hormone fragment that plays a crucial role in gastrointestinal function and neuroendocrine signaling. This bioactive peptide is involved in stimulating digestive processes, modulating appetite, and influencing anxiety-related behavior. Research applications include studies on gut-brain interactions, appetite regulation, and the pharmacological effects of peptide hormones in both physiological and pathological contexts. -
Gastrin/CCK-B Antagonist
CCK-B Receptor Antagonist 2 is a potent antagonist of the Gastrin/CCK-B receptor, exhibiting an IC50 of 0.43 nM. This compound also demonstrates inhibitory activity against the gastrin/CCK-A receptor with an IC50 of 1.82 μM. CCK-B Receptor Antagonist 2 serves as a valuable tool for research on gastrointestinal signaling and modulation of gastrin-related pathways, making it significant for studies concerning gastric function and disorders. -
Cholecystokinin Receptor Antagonist
Tarazepide is a potent antagonist of the cholecystokinin A (CCK-A) receptor. This compound inhibits CCK-A mediated signaling, demonstrating significant biological activity in modulating gastrointestinal functions and appetite regulation. Tarazepide is utilized in research applications related to digestion, metabolic disorders, and neurobiology, making it a valuable tool for studying the role of CCK receptors in various physiological processes. -
CCKB Receptor Antagonists
Pentagastrin meglumine is a selective antagonist of the Cholecystokinin B (CCKB) receptor, exhibiting an IC50 of 11 nM for CCKB and 1100 nM for CCKA. It plays a significant role in enhancing gastric mucosal defense mechanisms against acidity and provides protective effects on the gastric mucosa from experimental injury. This compound is valuable for research applications focused on gastrointestinal health and pathology. -
CCK2/gastrin Receptor Antagonist
Gastrazole is a potent and selective antagonist of the CCK2/gastrin receptor. This compound effectively reduces gastric acid levels and has been shown to inhibit gastrin-stimulated growth in pancreatic cancer cells. As such, Gastrazole is a valuable tool for research focused on gastrointestinal disorders and cancer biology. -
CCK2R Antagonist
GV150013X is a potent antagonist of the cholecystokinin-2/gastrin receptor (CCK2R), exhibiting a Ki value of 2.29 nM. This compound has demonstrated efficacy in attenuating central nervous system disorders, particularly in models of anxiety and panic disorder. Its application in research may provide valuable insights into the therapeutic potential for CCK2R modulation in neuropsychiatric conditions. -
CCK-B Receptor Antagonist
RP 72540 is a selective antagonist of the CCK-B receptor, exhibiting IC50 values of 2.4 nM, 1.2 nM, and 3.8 nM in guinea pig, rat, and mouse cerebral cortices, respectively. This compound effectively inhibits CCK-8-induced neuronal firing and demonstrates a dose-dependent reduction in gastric acid secretion. RP 72540 serves as a valuable tool in research applications aiming to elucidate the physiological roles of CCK-B receptors, particularly in the context of gastrointestinal processes and neurophysiology. -
Cholecystokinin Receptor
CI-1015 is a potent antagonist of the cholecystokinin B (CCK-B) receptor, which plays a critical role in gastrointestinal physiology and neurotransmission. This compound effectively inhibits CCK-B receptor activity, making it valuable for research into gastrointestinal disorders, anxiety, and pain modulation. Its specificity for the CCK-B receptor allows for the exploration of therapeutic avenues in conditions where CCK signaling is implicated. -
Appetite Suppressant
Ro 23-7014 is a cholecystokinin (CCK-7) analog that functions as an appetite suppressant. This compound modulates the central and peripheral pathways involved in energy homeostasis, making it valuable for research on obesity and metabolic disorders. Its ability to influence feeding behavior positions Ro 23-7014 as a relevant tool for exploring therapeutic targets in appetite regulation and weight management studies. -
Cholecystokinin Receptor
Mini Gastrin I, human is a truncated form of human gastrin, comprising amino acids 5-17 of the full peptide. It primarily targets the cholecystokinin receptor, playing a crucial role in gastrointestinal function by stimulating gastric acid secretion and promoting digestive enzyme release. This reagent is valuable for research in gastrointestinal physiology and the study of receptor signaling pathways associated with gastrin. -
CCKAR Small Molecule Agonist
CE-326597 is a small molecule agonist of the cholecystokinin A receptor (CCKAR). It selectively engages the lower region of the transmembrane domain pocket, offering unique insights into receptor activation that differ from the natural ligand CCK-8. This compound is valuable for studying metabolic disorders and gastrointestinal dysfunction, enabling researchers to explore the therapeutic potential of CCKAR modulation. -
CCK2R Antagonist
CI-988 meglumin is a potent cholecystokinin 2 receptor (CCK2R) antagonist. By inhibiting CCK2R, CI-988 meglumin plays a critical role in mitigating the gastrin-mediated cardioprotective effects associated with ischemia/reperfusion injury. This compound is valuable for research in cardiac physiology and pathophysiology, particularly in studies exploring receptor signaling and myocardial stress responses. -
C-terminal heptapeptide of CCK
CCK (27-33) is the C-terminal heptapeptide derived from cholecystokinin (CCK), which primarily targets CCK receptors. This peptide plays a significant role in stimulating gallbladder contraction and promoting pancreatic enzyme secretion, making it crucial for investigating digestive processes. CCK (27-33) is utilized in research applications focusing on gastrointestinal physiology and receptor signaling pathways.
